摘要
目的探讨利拉鲁肽联合门冬胰岛素30治疗2型糖尿病的临床疗效及安全性。方法将94例2型糖尿病患者按照随机对照法分为对照组(47例)和观察组(47例)。对照组给予门冬胰岛素30联合口服降糖药基础上,皮下注射地特胰岛素;观察组给予门冬胰岛素30联合口服降糖药基础上,皮下注射利拉鲁肽注射液;连续治疗16周后比较临床疗效。结果与治疗前比较,两组患者FPG、2 h PPG、Hb Alc及BMI均显著下降,差异有统计学意义(P<0.05),但治疗后两组FPG、2 h PPG及Hb Alc比较,差异无统计学意义(P>0.05),而治疗后观察组BMI较对照组下降更为明显,差异有统计学意义(P<0.05);在2型糖尿病患者应用利拉鲁肽期间,观察组血糖变异指标均小于对照组的血糖波动,差异有统计学意义(P<0.05);观察组低血糖发生率显著低于对照组。结论利拉鲁肽联合门冬胰岛素30治疗2型糖尿病可有效减少血糖波动,降低低血糖发生率,有效控制血糖水平。
OBJECTIVE To discuss the clinical curative effect and safety evaluation for Liraglutide alliance Insulin aspart 30 Treatment for type 2 diabetes. METHODS 94 eases of patients with type 2 diabetes, according to the randomized controlled method were random- ly divided into control group （n=47） and observation group （n=47）, control group given Insulin aspart 30 Combined oral medications and subcutaneous injection of insulin; observation group was given Insulin aspart 30 Based on the joint oral medications hypodermic injection Liraglutide; Continuous compare the clinical effect after 16 weeks of treatment. RESULTS Compared with before treatment, two groups of patients with FPG, 2 hPPG, HbAlc and BMI were significantly decreased （P〈0.05）, but the two groups after treatment FPG, 2 hPPG and HbAlc comparison difference bad no statistical significance （P〉0.05）, and observation group BMI down more obvi- ous compared with the control group after treatment （P〈0.05）; in patients with type 2 diabetes during application, lalu peptide, glu- cose variability index observation group were less than control group in blood glucose fluctuations （P〈0.05）; observation group hypogly- cemia incidence was significantly lower than the control group （8.51% VS0.00 %）.CONCLUSION Liraglutide alliance Insulin aspart 30 Treatment for type 2 diabetes could effectively reduce the blood sugar fluctuation, reduce the incidence of hypoglycemia and effec- tively control blood sugar levels.
出处
《中国初级卫生保健》
2016年第11期70-71,共2页
Chinese Primary Health Care
